CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics Limited - Ordinary Shares Stock Forecast & Price Prediction

Live CytoMed Therapeutics Limited - Ordinary Shares Stock (GDTC) Price
$2.62

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$2.62

P/E Ratio

-6.73

Volume Traded Today

$53,822

Dividend

Dividends not available for GDTC

52 Week High/low

5.50/1.20

CytoMed Therapeutics Limited - Ordinary Shares Market Cap

$28.7M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $GDTC ๐Ÿ›‘

Before you buy GDTC you'll want to see this list of ten stocks that have huge potential. Want to see if GDTC made the cut? Enter your email below

GDTC Summary

From what 0 stock analysts predict, the share price for CytoMed Therapeutics Limited - Ordinary Shares (GDTC) might decrease by 100% in the next year. This is based on a 12-month average estimation for GDTC. Price targets go from $ to $. The majority of stock analysts believe GDTC is a sell. Please note analyst price targets are not guaranteed and could be missed completely.

GDTC Analyst Ratings

CytoMed Therapeutics Limited - Ordinary Shares has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that CytoMed Therapeutics Limited - Ordinary Shares will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

GDTC stock forecast by analyst

These are the latest 20 analyst ratings of GDTC.

Analyst/Firm

Rating

Price Target

Change

Date

Bruce Jackson
Benchmark

Speculative Buy

$5

Reiterates

Oct 10, 2024
Bruce Jackson
Benchmark

Speculative Buy

$5

Reiterates

Jun 11, 2024
Bruce Jackson
Benchmark

Speculative Buy

$5

Reiterates

Dec 4, 2023
Bruce Jackson
Benchmark

Speculative Buy

$5

Initiates

Jul 21, 2023

GDTC Company Information

What They Do: Develops innovative cell-based immunotherapies.

Business Model: CytoMed Therapeutics Limited operates as a pre-clinical biopharmaceutical company that generates revenue through the development of novel immunotherapy products targeting human cancers and degenerative diseases. Its lead product, CTM-N2D, is currently in Phase I clinical trials, with additional candidates in various stages of development. The company collaborates with medical institutions for research and clinical trials, facilitating the advancement of its therapies.

Other Information: Founded in 2018 and based in Singapore, CytoMed is focused on harnessing advanced cellular therapies, including gamma delta T cells and mesenchymal stem cells. The company's strategic partnerships, such as the collaboration with Sengkang General Hospital, enhance its research capabilities and clinical validation efforts.
GDTC
CytoMed Therapeutics Limited - Ordinary Shares (GDTC)

When did it IPO

2023

Staff Count

0

Country

Singapore

Sector/Industry

Healthcare/Biotechnology

CEO

Dr. Wee Kiat Tan Ph.D.

Market Cap

$28.7M

CytoMed Therapeutics Limited - Ordinary Shares (GDTC) Financial Data

In 2023, GDTC generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that GDTC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$0

Revenue From 2021

$0

0.00 %
From Previous Year

Revenue From 2022

$0

0.00 %
From Previous Year

Revenue From 2023

$0

0.00 %
From Previous Year
  • Revenue TTM $339,500
  • Operating Margin TTM -736.0%
  • Gross profit TTM $0
  • Return on assets TTM -17.4%
  • Return on equity TTM -26.3%
  • Profit Margin 0.0%
  • Book Value Per Share 0.88%
  • Market capitalisation $28.7M
  • Revenue for 2021 $0
  • Revenue for 2022 $0
  • Revenue for 2023 $0
  • EPS this year (TTM) $-0.22

CytoMed Therapeutics Limited - Ordinary Shares (GDTC) Latest News

News Image

Tue, 20 Aug 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - The 74th Emerging Growth Conference is scheduled for August 21-22, 2024, as announced by EmergingGrowth.com, a small cap media portal.

Why It Matters - The Emerging Growth Conference showcases small-cap companies, influencing investor interest and potential stock movements in the sector, impacting market trends and investment strategies.

News Image

Wed, 17 Jul 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - CytoMed has been granted another patent for its Allogeneic Induced Pluripotent Stem Cell-derived Hybrid Gamma Delta Natural Killer T cells technology.

Why It Matters - The patent strengthens CytoMed's competitive position, potentially enhancing its market value and attracting investment interest in the biotech sector focused on innovative cancer therapies.

News Image

Wed, 20 Mar 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - CytoMed Therapeutics (NASDAQ:GDTC) has signed a research collaboration with Sengkang General Hospital to develop allogeneic cell-based immunotherapies for cancer treatment.

Why It Matters - The collaboration may enhance CytoMed's research capabilities and credibility, potentially leading to advancements in cancer treatment and impacting stock performance positively.

News Image

Mon, 18 Mar 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - CytoMed Therapeutics (NASDAQ: GDTC) will launch a pilot program on June 1, 2024, to isolate and cryo-store PBMCs for loyal shareholders, supporting its strategy for cell-based therapies.

Why It Matters - CytoMed's pilot program to collect and store PBMCs could enhance its therapeutic offerings and shareholder loyalty, potentially increasing its market value and attractiveness to investors.

News Image

Mon, 04 Mar 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - CytoMed Therapeutics has entered a research collaboration with Sengkang General Hospital to develop an injectable cartilage regeneration therapy using umbilical cord-derived stem cells, aiming for a Phase 1 trial in two years.

Why It Matters - CytoMed's collaboration with Sengkang General Hospital for a cartilage regeneration therapy could lead to significant advancements in regenerative medicine, potentially boosting stock value and market interest.

News Image

Mon, 29 Jan 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - The Company has secured exclusive patent rights in Malaysia, the US, and China, potentially enhancing its market position and product offerings.

Why It Matters - Exclusive patent rights in Malaysia, the US, and China can enhance the company's competitive edge, potentially increase revenue streams, and attract investment interest.

...

GDTC Frequently asked questions

The highest forecasted price for GDTC is $ from at .

The lowest forecasted price for GDTC is $ from from

The GDTC analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.